ImmunityBio, Inc. Common Stock (IBRX) — 分析摘要
ImmunityBio, Inc. Common Stock（IBRX）的市值为10.73十亿美元，最近一年的营收同比增长了+668.3%。净利润率为-310.2%。当前市盈率为-10.8倍。
核心要点
- 营收同比变化+668.3%
- 净利润率-310.2%
- 市盈率-10.8倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，IBRX的营收增长为+668.3%，市盈率为-10.8倍。
ImmunityBio, Inc. Common Stock (IBRX)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -151.9% — 严重经营亏损
净利率为 -598.6% — 亏损超过收入（可能含一次性费用）
股东权益为负，可能意味着资产负债表承压。
净利润较上一期下降 182.4%。
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
691
总部
SAN DIEGO, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。